ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

被引：6
|
作者：
Nichetti, Federico [1 ]
Lo Russo, Giuseppe [1 ]
Prelaj, Arsela [1 ]
Provenzano, Leonardo [1 ]
de Braud, Filippo [1 ,2 ]
Cabiddu, Mary [3 ]
Garassino, Marina Chiara [1 ]
Petrelli, Fausto [3 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy
来源：
THROMBOSIS RESEARCH | 2020年 / 194卷
关键词：
Non-Small-Cell Lung Cancer; Thromboembolic events; Thrombosis; ALK; ROS-1; Tyrosine kinase inhibitors; VENOUS THROMBOEMBOLISM;
D O I：
10.1016/j.thromres.2020.06.041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：176 / 177
页数：2
相关论文
共 50 条
  • [1] ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
    Ng, Terry L.
    Smith, Derek E.
    Mushtaq, Rao
    Patil, Tejas
    Dimou, Anastasios
    Yang, Shuo
    Liu, Qian
    Li, Xuefei
    Zhou, Caicun
    Jones, Robert T.
    Tu, Megan M.
    Yan, Flora
    Bowman, I. Alex
    Liu, Stephen, V
    Newkirk, Siera
    Bauml, Joshua
    Doebele, Robert C.
    Aisner, Dara L.
    Gao, Dexiang
    Ren, Shengxiang
    Camidge, D. Ross
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 596 - 605
  • [2] Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
    Rogers, Toni-Maree
    Russell, Prudence A.
    Wright, Gavin
    Wainer, Zoe
    Pang, Jia-Min
    Henricksen, Leigh A.
    Singh, Shalini
    Stanislaw, Stacey
    Grille, James
    Roberts, Esteban
    Solomon, Benjamin
    Fox, Stephen B.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 611 - 618
  • [3] ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events
    Ng, T.
    Smith, D.
    Mushtaq, R.
    Patil, T.
    Dimou, A.
    Yang, S.
    Liu, Q.
    Li, X.
    Zhou, C.
    Yan, F.
    Bowman, I. A.
    Liu, S.
    Doebele, R.
    Aisner, D.
    Ren, S.
    Camidge, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S357 - S358
  • [4] Detection of ALK and ROS1 rearrangements by immunocytochemistry on cytological samples
    Frankel, Diane
    Bourlard, Donatienne
    Garcia, Stephane
    Robaglia-Schlupp, Andree
    Peker, Emel
    Groliere, Adele
    Kaspi, Elise
    Roll, Patrice
    ANNALES DE PATHOLOGIE, 2019, 39 (03) : 227 - 236
  • [5] The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China
    Yi, Jiawen
    Chen, Huang
    Li, Jie
    Jiang, Xingran
    Xu, Yan
    Wang, Mengzhao
    Wang, Zheng
    Zhai, Zhenguo
    Ren, Yanhong
    Zhang, Yuhui
    THROMBOSIS JOURNAL, 2022, 20 (01)
  • [6] Complementary Utility of Combined ALK/ROS1 FISH with Immunohistochemistry for ALK/ROS1 Rearrangement Testing in Lung Cancer
    Nambirajan, A.
    Singh, V.
    Rana, D.
    Malik, P.
    Mohan, A.
    Jain, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1160 - S1160
  • [7] Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
    Song, Zhengbo
    Yu, Xinmin
    Zhang, Yiping
    CANCER BIOLOGY & THERAPY, 2017, 18 (11) : 883 - 887
  • [8] ALK and ROS1 Rearrangements Tested by Fluorescence In Situ Hybridization in Cytological Smears From Advanced Non-Small Cell Lung Cancer Patients
    Bozzetti, Cecilia
    Nizzoli, Rita
    Tiseo, Marcello
    Squadrilli, Anna
    Lagrasta, Costanza
    Buti, Sebastiano
    Gasparro, Donatello
    Zanoni, Daniele
    Majori, Maria
    De Filippo, Massimo
    Mazzoni, Francesca
    Maddau, Cristina
    Naldi, Nadia
    Sammarelli, Gabriella
    Frati, Caterina
    Pinto, Carmine
    Ardizzoni, Andrea
    DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 941 - 946
  • [9] ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours
    Yamamoto, Hidetaka
    Yoshida, Akihiko
    Taguchi, Kenichi
    Kohashi, Kenichi
    Hatanaka, Yui
    Yamashita, Atsushi
    Mori, Daisuke
    Oda, Yoshinao
    HISTOPATHOLOGY, 2016, 69 (01) : 72 - 83
  • [10] Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
    Clark, Jeffrey W.
    Camidge, D. Ross
    Kwak, Eunice L.
    Maki, Robert G.
    Shapiro, Geoffrey I.
    Chen, Isan
    Tan, Weiwei
    Randolph, Sophia
    Christensen, James G.
    Ozeck, Mark
    Tang, Yiyun
    Wilner, Keith D.
    Salgia, Ravi
    FUTURE ONCOLOGY, 2020, 16 (01) : 4289 - 4301
12345